KRYS - Krystal Biotech, Inc.
| Previous Close | 27.20 |
| Open | 26.71 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's Range | 26.65 - 28.74 |
| 52 Week Range | 13.66 - 38.95 |
| Volume | 138,946 |
| Avg. Volume | 105,096 |
| Market Cap | 414.531M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.05 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.50 |
- GlobeNewswire•4 days ago
Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2, first in-human trial of KB105, an HSV-1 based gene therapy engineered to deliver a human transglutaminase-1 (TGM1) gene to patients with TGM1-deficient autosomal recessive congenital ichthyosis (ARCI). TGM1-deficient ARCI is a debilitating rare skin disease characterized by excessive, thick scaling of the skin and causing multiple chronic health conditions.
- GlobeNewswire•last month
Krystal Biotech to Present at the RBC Capital Markets 2019 Healthcare Conference
PITTSBURGH, May 15, 2019 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that.
- GlobeNewswire•last month
Krystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, announced financial results for first quarter 2019 and an update on its business progress. “We are very pleased to have KB103 accepted into the PRIME program and believe that KB103 could potentially be a transformative treatment option for patients with dystrophic epidermolysis bullosa,” said Krish S. Krishnan, chairman and chief executive officer.
- GlobeNewswire•2 months ago
Krystal Biotech Announces Five Presentations of Clinical and Preclinical Data at the Society for Investigative Dermatology Annual Meeting
PITTSBURGH, April 29, 2019 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations.
- GlobeNewswire•3 months ago
EMA Grants PRIME Eligibility for KB103 to Treat Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, announced today that the European Medicines Agency (EMA) has granted access to its PRIME (PRIority MEdicines) scheme for KB103 (bercolagene telserpavec), a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB).
- GlobeNewswire•3 months ago
Krystal Biotech Reports 2018 Financial Results and Business Progress
Ancoris, a cGMP facility for clinical and commercial production of KB103, is operational following successful completion of a trial run. PITTSBURGH, March 12, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases announced financial results for 2018 and an update on its business progress. Commenting on the year, Krish S. Krishnan, chairman and chief executive officer, said, “2018 was a productive year for Krystal as we worked to become fully-integrated in the gene therapy space.
- Zacks•3 months ago
Krystal (KRYS) in Focus: Stock Moves 5.1% Higher
Krystal (KRYS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- GlobeNewswire•3 months ago
Krystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, announced today official opening of Ancoris, its new cGMP facility for clinical and commercial manufacture of its lead product KB103, following a successful trial run and the official inaugural ribbon cutting ceremony, held in Pittsburgh on March 5, 2019. The ribbon cutting ceremony was attended by City of Pittsburgh Mayor William Peduto, representatives from the Office of U.S. Senator Patrick J. Toomey and U. S. Senator Robert P. Casey, and Brett Kopelan, executive director of debra of America, a nonprofit organization providing all-inclusive support to the epidermolysis bullosa (EB) community.
- GlobeNewswire•3 months ago
Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli
Krystal Biotech Inc., (Krystal) (KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, announced that Julian S. Gangolli has been elected to Krystal’s Board of Directors and will serve as a member of the Nomination and Governance Committee, effective March 1, 2019. The appointment will increase the size of the Krystal Board of Directors to seven members. “Julian has a distinguished track record of successfully overseeing product commercialization launches in dermatology, rare disease and multiple other disease states, and will be an outstanding addition to our board,” said Krish S. Krishnan, chairman and chief executive officer of Krystal.
- GlobeNewswire•4 months ago
Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference
PITTSBURGH, March 01, 2019 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.
- GlobeNewswire•4 months ago
Krystal Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference
PITTSBURGH, Feb. 22, 2019 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.
- American City Business Journals•5 months ago
Danforth Advisors entering Pittsburgh, focusing on life sciences sector
Danforth Advisors, a Boston-area provider of financial and accounting services to the life sciences sector, has entered Pittsburgh. Founded in 2011, Danforth employs a team of consultants who are experienced accountants, corporate controllers and chief financial officers and specialists in financial planning and analysis. “Biotech companies are often pre-revenue stage and trying to build a business focused on science and getting things into the clinics,” said Robert Dickey IV, who joined Danforth last summer as managing director, Mid-Atlantic Region.
- GlobeNewswire•5 months ago
Krystal Biotech Completes Construction of Ancoris - A New GMP Facility for Commercial Manufacturing of a Viral Vector-Based Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that construction of Ancoris, a new state-of-the-art Good Manufacturing Practice (GMP) facility, is complete. The new facility is located near the Company’s headquarters in Pittsburgh and will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). “Our development of internal manufacturing capabilities bolsters our position for commercial readiness as we execute on our vision to bring our therapies to the patient communities in need,” said Krish S Krishnan, chairman and chief executive officer of Krystal Biotech.
- GlobeNewswire•6 months ago
Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Dec. 19, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare.
- GlobeNewswire•7 months ago
New Research Coverage Highlights VSE, Weyco Group, Funko, B. Riley Financial, Krystal Biotech, and Xcel Brands — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•7 months ago
Krystal Biotech to Present at Evercore ISI HealthCONx
PITTSBURGH, Nov. 20, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.
- GlobeNewswire•7 months ago
Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Krystal Biotech (KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported financial results for the third quarter ended September 30, 2018, and provided an update on the Company’s corporate progress. It is caused by mutations in the gene coding for type VII collagen, or COL7, a major component of the anchoring fibrils, which anchor the epidermis to the underlying dermis, and provide structural adhesion in a normal individual.
- GuruFocus.com•8 months ago
Krystal Biotech Inc (KRYS) President and CEO Krish S Krishnan Bought $500,000 of Shares
President and CEO of Krystal Biotech Inc (NASDAQ:KRYS) Krish S Krishnan bought 25,000 shares of KRYS on 10/18/2018 at an average price of $20 a share.
- PR Newswire•8 months ago
Chardan Serves as Lead Manager for Krystal Biotech
NEW YORK , Oct. 22, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced that the firm is acting as lead manager in the follow-on offering for Krystal Biotech, Inc. (NASDAQ: KRYS), a gene ...
